210 related articles for article (PubMed ID: 19504989)
21. [Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia].
Brémaud M; De Maistre E; Junke E; Guerci A; Lalot JM; Longrois D; Lecompte T; Meistelman C
Ann Fr Anesth Reanim; 2004 Feb; 23(1):50-5. PubMed ID: 14980323
[TBL] [Abstract][Full Text] [Related]
22. Management strategies for heparin-induced thrombocytopenia in heart-transplant candidates: case report and review of the literature.
Pamboukian SV; Ignaszewski AP; Ross HJ
J Heart Lung Transplant; 2000 Aug; 19(8):810-4. PubMed ID: 10967277
[TBL] [Abstract][Full Text] [Related]
23. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
von Segesser LK; Mueller X; Marty B; Horisberger J; Corno A
Perfusion; 2001 Sep; 16(5):411-6. PubMed ID: 11565896
[TBL] [Abstract][Full Text] [Related]
24. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
Ranze O; Ranze P; Magnani HN; Greinacher A
Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
[TBL] [Abstract][Full Text] [Related]
25. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal S; Manhas AH; Udden M; Rice L
Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
[TBL] [Abstract][Full Text] [Related]
26. Current agents for the treatment of patients with heparin-induced thrombocytopenia.
Warkentin TE
Curr Opin Pulm Med; 2002 Sep; 8(5):405-12. PubMed ID: 12172444
[TBL] [Abstract][Full Text] [Related]
27. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
[TBL] [Abstract][Full Text] [Related]
28. New treatment options for heparin-induced thrombocytopenia.
Ortel TL; Chong BH
Semin Hematol; 1998 Oct; 35(4 Suppl 5):26-34; discussion 35-6. PubMed ID: 9855181
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Jeske WP; Walenga JM
Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
[TBL] [Abstract][Full Text] [Related]
30. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Aouifi A; Blanc P; Piriou V; Bastien OH; Ffrench P; Hanss M; Lehot JJ
Ann Thorac Surg; 2001 Feb; 71(2):678-83. PubMed ID: 11235727
[TBL] [Abstract][Full Text] [Related]
31. Heparin-induced thrombocytopenia in intensive care patients.
Selleng K; Warkentin TE; Greinacher A
Crit Care Med; 2007 Apr; 35(4):1165-76. PubMed ID: 17334253
[TBL] [Abstract][Full Text] [Related]
32. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
Horlait G; Minet V; Mullier F; Michaux I
Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
[TBL] [Abstract][Full Text] [Related]
33. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial.
Carrier M; Robitaille D; Perrault LP; Pellerin M; Pagé P; Cartier R; Bouchard D
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):325-9. PubMed ID: 12579101
[TBL] [Abstract][Full Text] [Related]
34. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
Wilde MI; Markham A
Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
[TBL] [Abstract][Full Text] [Related]
35. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Magnani HN; Gallus A
Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
[TBL] [Abstract][Full Text] [Related]
36. [Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].
Verdy E; Debrix I; Benomar A; Becker A; Flahault A
Presse Med; 2007 May; 36(5 Pt 1):786-93. PubMed ID: 17303370
[TBL] [Abstract][Full Text] [Related]
37. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy.
Hassell K
Chest; 2005 Feb; 127(2 Suppl):1S-8S. PubMed ID: 15706025
[TBL] [Abstract][Full Text] [Related]
38. Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia.
Jackson MR; Danby CA; Alving BM
Ann Thorac Surg; 1997 Dec; 64(6):1815-7. PubMed ID: 9436582
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
40. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy.
Gill J; Kovacs MJ
Obstet Gynecol; 1997 Oct; 90(4 Pt 2):648-50. PubMed ID: 11770579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
